Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy

References

• Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest. 2011;121:1673–80. doi:10.1172/JCI45449. PMID:21659716.
   PubMed Web of Science ®Google Scholar
• Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007;17:253–76. doi:10.1002/rmv.535. PMID:17579921.
   PubMed Web of Science ®Google Scholar
• La Torre R, Nigro G, Mazzocco M, Best AM, Adler SP. Placental Enlargement in Women with Primary Maternal Cytomegalovirus Infection Is Associated with Fetal and Neonatal Disease. Clin Infect Dis. 2006;43:994–1000. doi:10.1086/507634. PMID:16983610.
   PubMed Web of Science ®Google Scholar
• Beam E, Razonable R. Cytomegalovirus in Solid Organ Transplantation: Epidemiology, Prevention, and Treatment. Curr Infect Dis Rep. 2012;14:633–41. doi:10.1007/s11908-012-0292-2. PMID:22992839.
   PubMed Web of Science ®Google Scholar
• Kotton CN. Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol. 2010;6:711–21. doi:10.1038/nrneph.2010.141. PMID:20978468.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113:5711–9. doi:10.1182/blood-2008-10-143560. PMID:19299333.
   PubMed Web of Science ®Google Scholar
• Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4:928–36. doi:10.1111/j.1600-6143.2004.00451.x. PMID:15147427.
   PubMed Web of Science ®Google Scholar
• Kotton CN. Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol. 2010;6:711–21. doi:10.1038/nrneph.2010.141. PMID:20978468.
   PubMed Web of Science ®Google Scholar
• Ariza-Heredia EJ, Nesher L, Chemaly RF. Cytomegalovirus diseases after hematopoietic stem cell transplantation: A mini-review. Cancer Lett. 2014;342:1–8. doi:10.1016/j.canlet.2013.09.004. PMID:24041869.
   PubMed Web of Science ®Google Scholar
• Revello MG, Gerna G. Diagnosis and Management of Human Cytomegalovirus Infection in the Mother, Fetus, and Newborn Infant. Clin Microbiol Rev. 2002;15:680–715. doi:10.1128/CMR.15.4.680-715.2002. PMID:12364375.
   PubMed Web of Science ®Google Scholar
• Bodeus M, Kabamba-Mukadi B, Zech F, Hubinont C, Bernard P, Goubau P. Human cytomegalovirus in utero transmission: follow-up of 524 maternal seroconversions. J Clin Virol. 2010;47:201–2. doi:10.1016/j.jcv.2009.11.009. PMID:20006542.
   PubMed Web of Science ®Google Scholar
• Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, Corey L, Hill J, Davis E, Flanigan C, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009;360:1191–9. doi:10.1056/NEJMoa0804749. PMID:19297572.
   PubMed Web of Science ®Google Scholar
• Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007;17:355–63. doi:10.1002/rmv.544. PMID:17542052.
   PubMed Web of Science ®Google Scholar
• Ross SA, Boppana SB. Congenital cytomegalovirus infection: outcome and diagnosis. Semin Pediatr Infect Dis. 2005;16:44–9. doi:10.1053/j.spid.2004.09.011. PMID:15685149.
   PubMedGoogle Scholar
• Schleiss MR. Cytomegalovirus Vaccine Development. Curr Top Microbiol Immunol. 2008;325:361–82. PMID:18637516.
   PubMed Web of Science ®Google Scholar
• Stratton KR, Durch JS, Lawrence RS. Vaccines for the 21st Century: A Tool for Decisionmaking. Inst Med. 2000. Washington (DC): National Academies Press (US). doi:10.17226/5501.
   Google Scholar
• Adler SP, Starr SE, Plotkin SA, Hempfling SH, Buis J, Manning ML, Manning ML, Best AM. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis. 1995;171:26–32. doi:10.1093/infdis/171.1.26. PMID:7798679.
   PubMed Web of Science ®Google Scholar
• Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA. 2003;289:1008–11. doi:10.1001/jama.289.8.1008. PMID:12597753.
   PubMed Web of Science ®Google Scholar
• Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med. 1992;326:663–7. doi:10.1056/NEJM199203053261003. PMID:1310525.
   PubMed Web of Science ®Google Scholar
• Nigro G, Adler SP, La Torre R, Best AM. Congenital Cytomegalovirus Collaborating Group. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med. 2005;353:1350–62. doi:10.1056/NEJMoa043337. PMID:16192480.
   PubMed Web of Science ®Google Scholar
• Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transplant. 2008;22:89–97. PMID:18217909.
   PubMed Web of Science ®Google Scholar
• Barron MA, Gao D, Springer KL, Patterson JA, Brunvand MW, McSweeney PA, Zeng C, Barón AE, Weinberg A. Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2009;49:1777–83. doi:10.1086/648423. PMID:19911937.
   PubMed Web of Science ®Google Scholar
• Landolfo S, Gariglio M, Gribaudo G, Lembo D. The human cytomegalovirus. Pharmacol Therapeutics. 2003;98:269–97. doi:10.1016/S0163-7258(03)00034-2.
   PubMed Web of Science ®Google Scholar
• Varnum SM, Streblow DN, Monroe ME, Smith P, Auberry KJ, Pasa-Tolic L, Wang D, Camp DG 2nd, Rodland K, Wiley S, et al. Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol. 2004;78:10960–6. doi:10.1128/JVI.78.20.10960-10966.2004. PMID:15452216.
   PubMed Web of Science ®Google Scholar
• Bankier AT, Beck S, Bohni R, Brown CM, Cerny R, Chee MS, Hutchison CA 3rd, Kouzarides T, Martignetti JA, Preddie E, et al. The DNA sequence of the human cytomegalovirus genome. Mitochondrial DNA. 1991;2:1–11.
   Google Scholar
• Cha TA, Tom E, Kemble GW, Duke GM, Mocarski ES, Spaete RR. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol. 1996;70:78–83. PMID:8523595.
   PubMed Web of Science ®Google Scholar
• Chee MS, Bankier AT, Beck S, Bohni R, Brown CM, Cerny R, Horsnell T, Hutchison CA 3rd, Kouzarides T, Martignetti JA, et al. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol. 1990;154:125–69. PMID:2161319.
   PubMed Web of Science ®Google Scholar
• Dolan A, Cunningham C, Hector RD, Hassan-Walker AF, Lee L, Addison C, Dargan DJ, McGeoch DJ, Gatherer D, Emery VC, et al. Genetic content of wild-type human cytomegalovirus. J Gen Virol. 2004;85:1301–12. doi:10.1099/vir.0.79888-0. PMID:15105547.
   PubMed Web of Science ®Google Scholar
• Gatherer D, Seirafian S, Cunningham C, Holton M, Dargan DJ, Baluchova K, Hector RD, Galbraith J, Herzyk P, Wilkinson GW, et al. High-resolution human cytomegalovirus transcriptome. Proc Natl Acad Sci U S A. 2011;108:19755–60. doi:10.1073/pnas.1115861108. PMID:22109557.
   PubMed Web of Science ®Google Scholar
• Stern-Ginossar N, Weisburd B, Michalski A, Le VT, Hein MY, Huang SX, Ma M, Shen B, Qian SB, Hengel H, et al. Decoding human cytomegalovirus. Science. 2012;338:1088–93. doi:10.1126/science.1227919. PMID:23180859.
   PubMed Web of Science ®Google Scholar
• Dunn W, Chou C, Li H, Hai R, Patterson D, Stolc V, Zhu H, Liu F. Functional profiling of a human cytomegalovirus genome. Proc Natl Acad Sci U S A. 2003;100:14223–8. doi:10.1073/pnas.2334032100. PMID:14623981.
   PubMed Web of Science ®Google Scholar
• Sinzger C, Digel M, Jahn G. Cytomegalovirus cell tropism. Curr Top Microbiol Immun. 2008;325:63–83.
   Google Scholar
• Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, Sleath PR, Grabstein KH, Hosken NA, Kern F, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202:673–85. doi:10.1084/jem.20050882. PMID:16147978.
   PubMed Web of Science ®Google Scholar
• Britt WJ, Mach M. Human cytomegalovirus glycoproteins. Intervirology. 1996;39:401–12. doi:10.1159/000150510. PMID:9130049.
   PubMed Web of Science ®Google Scholar
• Gretch DR, Kari B, Rasmussen L, Gehrz RC, Stinski MF. Identification and characterization of three distinct families of glycoprotein complexes in the envelopes of human cytomegalovirus. J Virol. 1988;62:875–81. PMID:2828682.
   PubMed Web of Science ®Google Scholar
• Xia L, Tang A, Meng W, Freed DC, He L, Wang D, Li F, Li L, Xiong W, Gui X, et al. Active evolution of memory B-cells specifc to viral gHgL pentameric complex in healthy subjects with silent human cytomegalovirus infection. Oncotarget. 2017;8:73654–69. doi:10.18632/oncotarget.18359.
   Web of Science ®Google Scholar
• Fouts AE, Chan P, Stephan JP, Vandlen R, Feierbach B. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol. 2012;86:7444–7. doi:10.1128/JVI.00467-12. PMID:22532696.
   PubMed Web of Science ®Google Scholar
• Loughney JW, Rustandi RR, Wang D, Troutman MC, Dick LW Jr, Li G, Sallusto F, Lanzavecchia A, Corti D, Gerna G. Soluble Human Cytomegalovirus gH/gL/pUL128-131 Pentameric Complex, but Not gH/gL, Inhibits Viral Entry to Epithelial Cells and Presents Dominant Native Neutralizing Epitopes. J Biol Chem. 2015;290:15985–95. doi:10.1074/jbc.M115.652230. PMID:25947373.
   PubMed Web of Science ®Google Scholar
• Smith MG. Propagation in Tissue Cultures of a Cytopathogenic Virus from Human Salivary Gland Virus (SGV) Disease. Exp Biol Med. 1956;92:424–30. doi:10.3181/00379727-92-22498.
   PubMed Web of Science ®Google Scholar
• Elek SD, Stern H. Development of a vaccine agaisnt mental retardation caused by cytomegalovirus infeciton in utero. Lancet. 1974;303:1–5. doi:10.1016/S0140-6736(74)92997-3.
   Google Scholar
• Plotkin SA, Furukawa T, Zygraich N, Huygelen C. Candidate HCMV strain for human vaccination. Infect Immun. 1975;12:521–7. PMID:170203.
   PubMed Web of Science ®Google Scholar
• Murphy E, Yu D, Grimwood J, Schmutz J, Dickson M, Jarvis MA, Hahn G, Nelson JA, Myers RM, Shenk TE. Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc Natl Acad Sci U S A. 2003;100:14976–81. doi:10.1073/pnas.2136652100. PMID:14657367.
   PubMed Web of Science ®Google Scholar
• Wang D, Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci U S A. 2005;102:18153–8. doi:10.1073/pnas.0509201102. PMID:16319222.
   PubMed Web of Science ®Google Scholar
• Murphy E, Shenk T. Human Cytomegalovirus Genome. Curr Top Microbiol Immunol. 2008;325:1–19.
   Google Scholar
• Gerna G, Sarasini A, Patrone M, Percivalle E, Fiorina L, Campanini G, Gallina A, Baldanti F, Revello MG. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol. 2008;89:853–65. doi:10.1099/vir.0.83523-0. PMID:18343825.
   PubMed Web of Science ®Google Scholar
• Yu D, Silva MC, Shenk T. Functional map of human cytomegalovirus AD169 defined by global mutational analysis. Proc Natl Acad Sci U S A. 2003;100:12396–401. doi:10.1073/pnas.1635160100. PMID:14519856.
   PubMed Web of Science ®Google Scholar
• Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G, Sarasini A, Wagner M, Gallina A, Milanesi G, Koszinowski U, et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol. 2004;78:10023–33. doi:10.1128/JVI.78.18.10023-10033.2004. PMID:15331735.
   PubMed Web of Science ®Google Scholar
• Wang D, Shenk T. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol. 2005;79:10330–8. doi:10.1128/JVI.79.16.10330-10338.2005. PMID:16051825.
   PubMed Web of Science ®Google Scholar
• Compton T. Receptors and immune sensors: the complex entry path of human cytomegalovirus. Trends Cell Biol. 2004;14:5–8. doi:10.1016/j.tcb.2003.10.009. PMID:14729174.
   PubMed Web of Science ®Google Scholar
• Fu TM, Wang D, Freed DC, Tang A, Li F, He X, Cole S, Dubey S, Finnefrock AC, ter Meulen J, et al. Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus. Vaccine. 2012;30:7469–74. doi:10.1016/j.vaccine.2012.10.053. PMID:23107592.
   PubMed Web of Science ®Google Scholar
• Krause PR, Bialek SR, Boppana SB, Griffiths PD, Laughlin CA, Ljungman P, Mocarski ES, Pass RF, Read JS, Schleiss MR, et al. Priorities for CMV vaccine development. Vaccine. 2013;32:4–10. doi:10.1016/j.vaccine.2013.09.042. PMID:24129123.
   PubMed Web of Science ®Google Scholar
• Fowler KB, Stagno S, Pass RF. Interval between Births and Risk of congeital CMV infection. Clin Infect Dis. 2004;38:1035–7. doi:10.1086/382533. PMID:15034839.
   PubMed Web of Science ®Google Scholar
• Morley PJ, Ertl P, Sweet C. Immunisation of Balb/c mice with severely attenuated murine cytomegalovirus mutants induces protective cellular and humoral immunity. J Med Virol. 2002;67:187–99. doi:10.1002/jmv.2207. PMID:11992579.
   PubMed Web of Science ®Google Scholar
• Shanley JD, Wu CA. Mucosal immunization with a replication-deficient adenovirus vector expressing murine cytomegalovirus glycoprotein B induces mucosal and systemic immunity. Vaccine. 2003;21:2632–42. doi:10.1016/S0264-410X(03)00037-9. PMID:12744900.
   PubMed Web of Science ®Google Scholar
• Shanley JD, Wu CA. Intranasal immunization with a replication-deficient adenovirus vector expressing glycoprotein H of murine cytomegalovirus induces mucosal and systemic immunity. Vaccine. 2005;23:996–1003. doi:10.1016/j.vaccine.2004.07.041. PMID:15620472.
   PubMed Web of Science ®Google Scholar
• González Armas JC, Morello CS, Cranmer LD, Spector DH. DNA immunization confers protection against murine cytomegalovirus infection. J Virol. 1996;70:7921–8. PMID:8892915.
   PubMed Web of Science ®Google Scholar
• Morello CS, Ye M, Hung S, Kelley LA, Spector DH. Systemic Priming-Boosting Immunization with a Trivalent Plasmid DNA and Inactivated Murine Cytomegalovirus (MCMV) Vaccine Provides Long-Term Protection against Viral Replication following Systemic or Mucosal MCMV Challenge. J Virol. 2005;79:159–75. doi:10.1128/JVI.79.1.159-175.2005. PMID:15596812.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang H, Wu S, Chang H, Liu L, Peng B, Fang F, Chen Z. Comparison of multiple DNA vaccines for protection against cytomegalovirus infection in BALB/c mice. Virol J. 2014;11:104. doi:10.1186/1743-422X-11-104. PMID:24898886.
   PubMed Web of Science ®Google Scholar
• Schleiss MR, Heineman TC. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines. 2005;4:381–406. doi:10.1586/14760584.4.3.381. PMID:16026251.
   PubMed Web of Science ®Google Scholar
• Mcvoy MA. Cytomegalovirus Vaccines. Clin Infect Dis. 2013;57:S196–9. doi:10.1093/cid/cit587. PMID:24257427.
   PubMed Web of Science ®Google Scholar
• Wang D, Li F, Freed DC, Finnefrock AC, Tang A, Grimes SN, Casimiro DR, Fu TM. Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection. Vaccine. 2011;29:9075–80. doi:10.1016/j.vaccine.2011.09.056. PMID:21945962.
   PubMed Web of Science ®Google Scholar
• Gerna G. Endothelial cells and CMV dissemination. Future Microbiol. 2012;7:441–4. doi:10.2217/fmb.12.12. PMID:22439720.
   PubMed Web of Science ®Google Scholar
• Smith MS, Bentz GL, Alexander JS, Yurochko AD. Human cytomegalovirus induces monocyte differentiation and migration as a strategy for dissemination and persistence. J Virol. 2004;78:4444–53. doi:10.1128/JVI.78.9.4444-4453.2004. PMID:15078925.
   PubMed Web of Science ®Google Scholar
• Saccoccio FM, Gallagher MK, Adler SP, McVoy MA. Neutralizing activity of saliva against cytomegalovirus. Clin Vaccine Immunol. 2011;18:1536–42. doi:10.1128/CVI.05128-11. PMID:21795465.
   PubMed Web of Science ®Google Scholar
• Cui X, Meza BP, Adler SP, McVoy MA. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine. 2008;26:5760–6. doi:10.1016/j.vaccine.2008.07.092. PMID:18718497.
   PubMed Web of Science ®Google Scholar
• Pereira L, Maidji E. Cytomegalovirus infection in the human placenta: maternal immunity and developmentally regulated receptors on trophoblasts converge. Curr Top Microbiol Immunol. 2008;325:383–95. PMID:18637517.
   PubMed Web of Science ®Google Scholar
• Lilleri D, Kabanova A, Revello MG, Percivalle E, Sarasini A, Genini E, Sallusto F, Lanzavecchia A, Corti D, Gerna G. Human Cytomegalovirus Transmission Correlates with Delayed Maternal Antibodies to gH/gL/pUL128-130-131 Complex during Primary Infection. PloS One. 2013;8:e59863. doi:10.1371/journal.pone.0059863. PMID:23555812.
   PubMed Web of Science ®Google Scholar
• Furione M, Rognoni V, Sarasini A, Zavattoni M, Lilleri D, Gerna G, Revello MG. Slow increase in IgG avidity correlates with prevention of human cytomegalovirus transmission to the fetus. J Med Virol. 2013;85:1960–7. doi:10.1002/jmv.23691. PMID:23893782.
   PubMed Web of Science ®Google Scholar
• Ross SA, Fowler KB, Ashrith G, Stagno S, Britt WJ, Pass RF, Boppana SB. Hearing loss in children with congenital cytomegalovirus infection born to mothers with preexisting immunity. J Pediatr. 2006;148:332–6. doi:10.1016/j.jpeds.2005.09.003. PMID:16615962.
   PubMed Web of Science ®Google Scholar
• Yamamoto AY, Mussi-Pinhata MM, Isaac Mde L, Amaral FR, Carvalheiro CG, Aragon DC, Manfredi AK, Boppana SB, Britt WJ. Congenital cytomegalovirus infection as a cause of sensorineural hearing loss in a highly immune population. Pediatr Infect Dis J. 2011;30:1043–6. doi:10.1097/INF.0b013e31822d9640. PMID:21814153.
   PubMed Web of Science ®Google Scholar
• Lilleri D, Kabanova A, Revello MG, Percivalle E, Sarasini A, Genini E, Sallusto F, Lanzavecchia A, Corti D, Gerna G. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PLoS One. 2013;8:e59863. doi:10.1371/journal.pone.0059863. PMID:23555812.
   PubMed Web of Science ®Google Scholar
• Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R, Adler SP. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients. J Clin Virol. 2006;35:332–7. doi:10.1016/j.jcv.2005.09.019. PMID:16387547.
   PubMed Web of Science ®Google Scholar
• Riddell SR, Greenberg PD. T-cell therapy of cytomegalovirus and human immunodeficiency virus infection. J Antimicrob Chemother. 2000;45:35–43. doi:10.1093/jac/45.suppl_4.35. PMID:10855770.
   PubMed Web of Science ®Google Scholar
• Reddehase MJ, Mutter W, Münch K, Bühring HJ, Koszinowski UH. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol. 1987;61:3102–8. PMID:3041033.
   PubMed Web of Science ®Google Scholar
• Quinnan GV, Kirmani N, Rook AH, Manischewitz JF, Jackson L, Moreschi G, Santos GW, Saral R, Burns WH. Cytotoxic T Cells in Cytomegalovirus Infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med. 1982;307:7–13. doi:10.1056/NEJM198207013070102. PMID:6281647.
   PubMed Web of Science ®Google Scholar
• Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 1991;78:1373–80. PMID:1652311.
   PubMed Web of Science ®Google Scholar
• Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood. 1994 83:1971–9. PMID:8142663.
   PubMed Web of Science ®Google Scholar
• Einsele H. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99:3916–22. doi:10.1182/blood.V99.11.3916. PMID:12010789.
   PubMed Web of Science ®Google Scholar
• Khanna R, Diamond DJ. Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol Med. 2006;12:26–33. doi:10.1016/j.molmed.2005.11.006. PMID:16337831.
   PubMed Web of Science ®Google Scholar
• Neff BJ, Weibel RE, Buynak EB, McLean AA, Hilleman MR. Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169. Proc Soc Exp Biol Med. 1979;160:32–7. doi:10.3181/00379727-160-40382.
   PubMed Web of Science ®Google Scholar
• Stern H. Live cytomegalovirus vaccination of healthy volunteers: eight year follow-up studies. Birth Defects Orig Artic Ser. 1984;20:263–9. PMID:6329366.
   PubMedGoogle Scholar
• Gehrz RC, Christianson WR, Linner KM, Groth KE, Balfour HH Jr. CYtomegalovirus vaccine. Arch Intern Med. 1980;140:936–9. doi:10.1001/archinte.1980.00040020936013. PMID:6247988.
   PubMedGoogle Scholar
• Plotkin SA, Farquhar J, Horberger E. Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. J Infect Dis. 1976;134:470–5. doi:10.1093/infdis/134.5.470. PMID:186541.
   PubMed Web of Science ®Google Scholar
• Schleiss M. Progress in Cytomegalovirus vaccine development. Herpes. 2005;12:66–75. PMID:16393522.
   PubMedGoogle Scholar
• Plotkin SA, Higgins R, Kurtz JB, Morris PJ, Campbell DA Jr, Shope TC, Spector SA, Dankner WM. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation. 1994 58:1176–8. PMID:7992358.
   PubMed Web of Science ®Google Scholar
• Glazer JP, Friedman HM, Grossman RA, Starr SE, Barker CF, Perloff LJ, Huang ES, Plotkin SA. Live cytomegalovirus vaccination of renal transplant candidates. Ann Intern Med. 1979;91:676–83. doi:10.7326/0003-4819-91-5-676.
   PubMed Web of Science ®Google Scholar
• Marker SC, Simmons RL, Balfour HH Jr. Cytomegalovirus vaccine in renal allograft recipients. Transplant Proc. 1981;13:117–9. PMID:6267748.
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Smiley ML, Friedman HM, Starr SE, Fleisher GR, Wlodaver C, Dafoe DC, Friedman AD, Grossman RA, Barker CF. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet. 1984;1:528–30. doi:10.1016/S0140-6736(84)90930-9. PMID:6142252.
   PubMed Web of Science ®Google Scholar
• Brayman KL, Dafoe DC, Smythe WR, Barker CF, Perloff LJ, Naji A, Fox IJ, Grossman RA, Jorkasky DK, Starr SE, et al. Prophylaxis of serious cytomegalovirus infection in renal transplant candidates using live human cytomegalovirus vaccine. Arch Surg. 1988;123:1502–8. doi:10.1001/archsurg.1988.01400360072012. PMID:2847687.
   PubMedGoogle Scholar
• Plotkin SA, Starr SE, Friedman HM, Brayman K, Harris S, Jackson S, Tustin NB, Grossman R, Dafoe D, Barker C. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant.A controlled trial. Ann Intern Med. 1991;114:525–31. doi:10.7326/0003-4819-114-7-525. PMID:1848053.
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Huang ES. Cytomegalovirus vaccine virus (Towne strain) does not induce latency. J Infect Dis. 1985;152:395–7. doi:10.1093/infdis/152.2.395. PMID:2993436.
   PubMed Web of Science ®Google Scholar
• Kemble G, Duke G, Winter R, Spaete R. Defined large-scale alterations of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids. J Virol. 1996;70:2044–8. PMID:8627734.
   PubMed Web of Science ®Google Scholar
• Heineman TC, Schleiss M, Bernstein DI, Spaete RR, Yan L, Duke G, Prichard M, Wang Z, Yan Q, Sharp MA, et al. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis. 2006;193:1350–60. doi:10.1086/503365. PMID:16619181.
   PubMed Web of Science ®Google Scholar
• Bradley AJ, Lurain NS, Ghazal P, Trivedi U, Cunningham C, Baluchova K, Gatherer D, Wilkinson GW, Dargan DJ, Davison AJ. High-throughput sequence analysis of variants of human cytomegalovirus strains Towne and AD169. J Gen Virol. 2009;90:2375–80. doi:10.1099/vir.0.013250-0. PMID:19553388.
   PubMed Web of Science ®Google Scholar
• Gerna G, Percivalle E, Sarasini A, Baldanti F, Campanini G, Revello MG. Rescue of human cytomegalovirus strain AD169 tropism for both leukocytes and human endothelial cells. J Gen Virol. 2003;84:1431–6. doi:10.1099/vir.0.19055-0. PMID:12771411.
   PubMed Web of Science ®Google Scholar
• Gerna G, Percivalle E, Sarasini A, Baldanti F, Revello MG. The attenuated Towne strain of human cytomegalovirus may revert to both endothelial cell tropism and leuko- (neutrophil- and monocyte-) tropism in vitro. J Gen Virol. 2002;83:1993–2000. doi:10.1099/0022-1317-83-8-1993. PMID:12124463.
   PubMed Web of Science ®Google Scholar
• McVoy MA. Cytomegalovirus vaccines. Clin Infect Dis. 2013;57(Suppl 4):S196–9. doi:10.1093/cid/cit587. PMID:24257427.
   PubMed Web of Science ®Google Scholar
• Britt WJ, Vugler L, Butfiloski EJ, Stephens EB. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV recombinant vaccinia virus infected cells in analysis of the human neutralizing antibody response. J Virol. 1990;64:1079–85. PMID:2154594.
   PubMed Web of Science ®Google Scholar
• Marshall GS, Rabalais GP, Stout GG, Waldeyer SL. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J Infect Dis. 1992;165:381–4. doi:10.1093/infdis/165.2.381. PMID:1309850.
   PubMed Web of Science ®Google Scholar
• Spaete RR. A recombinant subunit vaccine approach to HCMV vaccine development. Transplant Proc. 1991;23:90–6. PMID:1648843.
   PubMed Web of Science ®Google Scholar
• Frey SE, Harrison C, Pass RF, Yang E, Boken D, Sekulovich RE, Percell S, Izu AE, Hirabayashi S, Burke RL, et al. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J Infect Dis. 1999;180:1700–3. doi:10.1086/315060. PMID:10515836.
   PubMed Web of Science ®Google Scholar
• Pass RF, Duliegè AM, Boppana S, Sekulovich R, Percell S, Britt W, Burke RL. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis. 1999;180:970–5. doi:10.1086/315022. PMID:10479120.
   PubMed Web of Science ®Google Scholar
• Mitchell DK, Holmes SJ, Burke RL, Duliege AM, Adler SP Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J. 2002;21:133–8 doi:10.1097/00006454-200202000-00009. PMID:11840080.
   PubMed Web of Science ®Google Scholar
• Zhang C, Pass RF. Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine. Vaccine. 2004;23:507–10. doi:10.1016/j.vaccine.2004.06.027. PMID:15530699.
   PubMed Web of Science ®Google Scholar
• Sabbaj S, Pass RF, Goepfert PA, Pichon S. Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. J Infect Dis. 2011;203:1534–4. doi:10.1093/infdis/jir138. PMID:21592981.
   PubMed Web of Science ®Google Scholar
• Potzsch S, Spindler N, Wiegers AK, Fisch T, Rucker P, Sticht H, Grieb N, Baroti T, Weisel F, Stamminger T, et al. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog. 2011;7:e1002172. doi:10.1371/journal.ppat.1002172. PMID:21852946.
   PubMed Web of Science ®Google Scholar
• McLaughlin-Taylor E, Pande H, Forman SJ, Tanamachi B, Li CR, Zaia JA, Greenberg PD, Riddell SR. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol. 1994;43:103–10. doi:10.1002/jmv.1890430119. PMID:8083644.
   PubMed Web of Science ®Google Scholar
• Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, Sissons JG. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol. 1996;70:7569–79. PMID:8892876.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK, Guterwill DF, Smith LR, Rolland AP, Kenney RT. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12:290–99. doi:10.1016/S1473-3099(11)70344-9. PMID:22237175.
   PubMed Web of Science ®Google Scholar
• Slezak SL, Bettinotti M, Selleri S, Adams S, Marincola FM, Stroncek DF. CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects. J Transl Med. 2007;5:17. doi:10.1186/1479-5876-5-17. PMID:17391521.
   PubMed Web of Science ®Google Scholar
• Vilalta A, Mahajan RK, Hartikka J, Rusalov D, Martin T, Bozoukova V, Leamy V, Hall K, Lalor P, Rolland A, Kaslow DC. I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration. Hum Gene Ther. 2005;16:1143–50. doi:10.1089/hum.2005.16.1143. PMID:16218775.
   PubMed Web of Science ®Google Scholar
• Jacobson MA, Adler SP, Sinclair E, Black D, Smith A, Chu A, Moss RB, Wloch MK. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). Vaccine. 2009;27:1540–8. doi:10.1016/j.vaccine.2009.01.006. PMID:19168107.
   PubMed Web of Science ®Google Scholar
• Adler SP, Plotkin SA, Gonczol E, Cadoz M, Meric C, Wang JB, Dellamonica P, Best AM, Zahradnik J, Pincus S, et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis. 1999;180:843–6 doi:10.1086/314951. PMID:10438376.
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Schleiss MR, Berencsi K, Gonczol E, Dickey M, Khoury P, Cadoz M, Meric C, Zahradnik J, Duliege AM, Plotkin S. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J Infect Dis. 2002;185:686–90. doi:10.1086/339003. PMID:11865427.
   PubMed Web of Science ®Google Scholar
• Wang D, Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA. 2005;102:18153–8. doi:10.1073/pnas.0509201102. PMID:16319222.
   PubMed Web of Science ®Google Scholar
• Revello MG, Gerna G. Human cytomegalovirus tropism for endothelial/epithelial cells: scientific background and clinical implications. Rev Med Virol. 2010;20:136–55. doi:10.1002/rmv.645. PMID:20084641.
   PubMed Web of Science ®Google Scholar
• Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG, Gerna G, Sallusto F, Lanzavecchia A. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol. 2010;84:1005–13. doi:10.1128/JVI.01809-09. PMID:19889756.
   PubMed Web of Science ®Google Scholar
• Freed DC, Tang Q, Tang A, Li F, He X, Huang Z, Meng W, Xia L, Finnefrock AC, Durr E, et al. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine. Proc Natl Acad Sci U S A. 2013;110:E4997–5005. doi:10.1073/pnas.1316517110. PMID:24297878.
   PubMed Web of Science ®Google Scholar
• Wang D, Freed DC, He X, Li F, Tang A, Cox KS, Dubey SA, Cole S, Medi MB, Liu Y, et al. A replication-defective human cytomegalovirus vaccine for prevention of congenital infection. Sci Transl Med. 2016;8:362ra145. doi:10.1126/scitranslmed.aaf9387. PMID:27797961.
   PubMed Web of Science ®Google Scholar
• Wille PT, Wisner TW, Ryckman B, Johnson DC. Human cytomegalovirus (HCMV) glycoprotein gB promotes virus entry in trans acting as the viral fusion protein rather than as a receptor-binding protein. MBio. 2013;4:1–9. doi:10.1128/mBio.00332-13.
   Web of Science ®Google Scholar
• Cunningham AL. The herpes zoster subunit vaccine. Expert Opin Biol Ther. 2016;16:265–71. doi:10.1517/14712598.2016.1134481. PMID:26865048.
   PubMed Web of Science ®Google Scholar
• Roth K, Ferreira VH, Kaushic C. HSV-2 vaccine: current state and insights into development of a vaccine that targets genital mucosal protection. Microb Pathog. 2013;58:45–54. doi:10.1016/j.micpath.2012.11.001. PMID:23159485.
   PubMed Web of Science ®Google Scholar
• Stanberry LR. HERPES. Dermatol Clin. 1998;16:811–6. doi:10.1016/S0733-8635(05)70052-8. PMID:9891686.
   PubMedGoogle Scholar
• White CJ, Kuter BJ, Hildebrand CS, Isganitis KL, Matthews H, Calandra GB, Provost PJ, Ellis RW, Gerety RJ, Calandra GB. Varicella Vaccine (VARIVAX) in Healthy Children and Adolescents: Results From Clinical Trials, 1987 to 1989. Pediatrics. 1991;87:604–10. PMID:1850506.
   PubMed Web of Science ®Google Scholar
• Keating GM. Shingles (Herpes Zoster) Vaccine (Zostavax): A Review in the Prevention of Herpes Zoster and Postherpetic Neuralgia. BioDrugs. 2016;30:243–54. doi:10.1007/s40259-016-0180-7. PMID:27189459.
   PubMed Web of Science ®Google Scholar
• Pepperl S, Münster J, Mach M, Harris JR, Plachter B. Dense Bodies of Human Cytomegalovirus Induce both Humoral and Cellular Immune Responses in the Absence of Viral Gene Expression. J Virol. 2000;74:6132–46. doi:10.1128/JVI.74.13.6132-6146.2000. PMID:10846097.
   PubMed Web of Science ®Google Scholar
• Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O'Beirne J, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011;377:1256–63. doi:10.1016/S0140-6736(11)60136-0. PMID:21481708.
   PubMed Web of Science ®Google Scholar
• Reap EA, Morris J, Dryga SA, Maughan M, Talarico T, Esch RE, Negri S, Burnett B, Graham A, Olmsted RA, et al. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine. 2007;25:7441–9. doi:10.1016/j.vaccine.2007.08.016. PMID:17870214.
   PubMed Web of Science ®Google Scholar
• Loomis RJ, Lilja AE, Monroe J, Balabanis KA, Brito LA, Palladino G, Franti M, Mandl CW, Barnett SW, Mason PW. Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies. Vaccine. 2013;31:919–26. doi:10.1016/j.vaccine.2012.12.009. PMID:23246547.
   PubMed Web of Science ®Google Scholar
• Berencsi K, Gyulai Z, Gönczöl E, Pincus S, Cox WI, Michelson S, Kari L, Meric C, Cadoz M, Zahradnik J, et al. A Canarypox Vector–Expressing Cytomegalovirus (CMV) Phosphoprotein 65 Induces Long-Lasting Cytotoxic T Cell Responses in Human CMV-Seronegative Subjects. J Infect Dis. 2001;183:1171–9. doi:10.1086/319680. PMID:11262198.
   PubMed Web of Science ®Google Scholar
• Wang Z, La Rosa C, Lacey SF, Maas R, Mekhoubad S, Britt WJ, Diamond DJ. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. J Clin Virol. 2006;35:324–31. doi:10.1016/j.jcv.2005.09.018. PMID:16388983.
   PubMed Web of Science ®Google Scholar
• Saccoccio FM, Sauer AL, Cui X, Armstrong AE, Habib el-SE, Johnson DC, Ryckman BJ, Klingelhutz AJ, Adler SP, McVoy MA. Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells. Vaccine. 2011;29:2705–11. doi:10.1016/j.vaccine.2011.01.079. PMID:21310190.
   PubMed Web of Science ®Google Scholar